About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Leads a $57 million Senior Preferred Equity Financing for EndoChoice

NEW YORK,NY. (March 3, 2015 – draft) – Deerfield today announced the close of a $57 million senior preferred equity financing in EndoChoice.  Deerfield led a group of new and existing investors in the financing.  Proceeds will go toward continued expansion of sales and marketing efforts of the Fuse Full Spectrum Endoscopy® platform; Fuse has demonstrated in a peer-reviewed publication a lower adenoma miss rate relative to standard forward-viewing colonoscopy and may improve the efficacy of colorectal cancer screening and surveillance.

“We are delighted to be able to lead this growth financing for EndoChoice,” said Steven Hochberg, Partner at Deerfield. “This is a unique opportunity to invest in a company that has a broad range of Gastrointestinal products and services, a track record of 7 years of growth, and an exciting, new endoscopy technology that promises to improve clinical outcomes while lowering healthcare costs.” 

“As a growth company, the addition of Deerfield and the other new investors to our team provides us with further momentum to enhance our Company’s capabilities,” said Mark Gilreath, Founder and CEO at EndoChoice.  “We are well positioned to expand our commercial and product development efforts to ensure that more patients around the world will benefit from this potentially life-saving technology.”

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.   For more information, please visit

About EndoChoice

Based in the Atlanta GA area, ECPM Holdings, LLC (EndoChoice) is a medtech company focused on the manufacturing and commercialization of platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 25 countries. The Company was founded in 2008 and has rapidly developed abroad and innovative product portfolio, which includes the revolutionary Full Spectrum Endoscopy System (Fuse). The Fuse colonoscope uses three cameras to provide GI specialists with a 330 degree field of view as compared to the 140 to 170 degree field of view from standard colonoscopies, while the Fuse gastroscope uses two cameras to provide a 245 degree field of view as compared to the 150 degree field of view provided by standard gastroscopes. For more information, please visit


Deerfield Management Company
Karen Heidelberger, 212-692-7140
[email protected]